Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second line, or combination therapies. Herein we review the most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma.
Citations
Citations to this article as recorded by
Construction of a multifunctional drug-delivery platform with fluorescence sensing and β-elemene loading for inhibiting the proliferation of hepatocellular carcinoma cells Chaoyu Liu, Xiuhong Pan, Zhen Xiao, Mingyu Qiao, Zhe Tian, Guiyou Wu, Zhongshi Huang, Xiaoying Zhu Journal of Molecular Structure.2026; 1354: 144865. CrossRef
Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation” Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun Clinical and Molecular Hepatology.2026; 32(1): 436. CrossRef
Calculus bovis inhibits liver cancer via the Wnt/β-catenin pathway Jian-Qiang Chen, Xiang Lan World Journal of Gastroenterology.2025;[Epub] CrossRef
Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma Chen Huang, Yangqian Li, Fengmei Zhang, Chenliang Zhang, Zhenyu Ding International Journal of Surgery.2025; 111(4): 2990. CrossRef
Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex Snehal K. Shukla, Mimansa Goyal, Dipti D. Kanabar, Seyoum Ayehunie, Bhavesh Deore, Carlos A. Sanhueza, Aaron Muth, Vivek Gupta Journal of Molecular Liquids.2024; 401: 124701. CrossRef
Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms Jinhong Guo, Wenjie Yan, Hao Duan, Diandian Wang, Yaxi Zhou, Duo Feng, Yue Zheng, Shiqi Zhou, Gaigai Liu, Xia Qin Nutrients.2024; 16(11): 1642. CrossRef
Construction of a Novel Diagnostic Model Based on Ferroptosis-Related Genes for Hepatocellular Carcinoma Using Machine and Deep Learning Methods Shiming Yi, Chunlei Zhang, Ming Li, Jiafeng Wang, Zhongjie Shi Journal of Oncology.2023; 2023: 1. CrossRef
Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis Zhaoxia Sun, Li Zhao, Shuang Wang, Honggang Wang Annals of Hepatology.2022; 27: 100571. CrossRef
Remifentanil reduces the proliferation, migration and invasion of HCC cells via lncRNA NBR2/miR‐650/TIMP3 axis Wei Liang, Jinyuan Ke International Journal of Experimental Pathology.2022; 103(2): 44. CrossRef
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim BMC Gastroenterology.2022;[Epub] CrossRef
The pathogenesis of liver cancer and the therapeutic potential of bioactive substances Song Gao, Xingyue Jiang, Liang Wang, Shanshan Jiang, Hanyuan Luo, Yan Chen, Cheng Peng Frontiers in Pharmacology.2022;[Epub] CrossRef
Potential Therapeutic Strategies to Combat HCC Sidra Altaf, Faiza Saleem, Azam Ali Sher, Ashiq Ali Current Molecular Pharmacology.2022; 15(7): 929. CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(5): 1317. CrossRef
Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells Tae Ho Hong, M. T. Jeena, Ok-Hee Kim, Kee-Hwan Kim, Ho Joong Choi, Kyung Hee Lee, Ha-Eun Hong, Ja-Hyoung Ryu, Say-June Kim Scientific Reports.2021;[Epub] CrossRef
Long Non-coding RNA MAFG-AS1 Promotes Cell Proliferation, Migration, and EMT by miR-3196/STRN4 in Drug-Resistant Cells of Liver Cancer Tianming Chen, Bin Huang, Yaozhen Pan Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Cancers.2021; 14(1): 67. CrossRef
Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea Myung Ji Goh, Joo Hyun Oh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik Liver Cancer.2021; 10(1): 52. CrossRef
Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon International Journal of Molecular Sciences.2020; 21(2): 472. CrossRef
Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients Kang Hyun Park, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung Chul Yoo, Jin Ho Hwang, Sang Woo Park, Young Jun Kim, Hee Sun Park, Mi Hye Yu, Hae Jeong Jeon The Korean Journal of Gastroenterology.2020; 75(3): 147. CrossRef
Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on “Unification of Medicines and Excipients”
Jiayi Zhu, Yanling Huang, Jiquan Zhang, Yi Feng, Lan Shen Drug Design, Development and Therapy.2020; Volume 14: 1481. CrossRef
EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1 Dong Jun Park, Pil Soo Sung, Jung-Hee Kim, Gil Won Lee, Jeong Won Jang, Eun Sun Jung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Journal for ImmunoTherapy of Cancer.2020; 8(1): e000301. CrossRef
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2020; 26(3): 328. CrossRef
Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma Pil Soo Sung, Sung Woo Cho, Jaejun Lee, Hyun Yang, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Journal of Liver Cancer.2020; 20(2): 128. CrossRef
The disubstituted adamantyl derivative LW1564 inhibits the growth of cancer cells by targeting mitochondrial respiration and reducing hypoxia-inducible factor (HIF)-1α accumulation Inhyub Kim, Minkyoung Kim, Min Kyung Park, Ravi Naik, Jae Hyung Park, Bo-Kyung Kim, Yongseok Choi, Kwan Young Chang, Misun Won, Hyun Seung Ban, Kyeong Lee Experimental & Molecular Medicine.2020; 52(11): 1845. CrossRef
Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma Ya Li, Qiuju Han, Huajun Zhao, Quanjuan Guo, Jian Zhang Frontiers in Pharmacology.2020;[Epub] CrossRef
Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma Hee Chul Nam, Pil Soo Sung, Do Seon Song, Jung Hyun Kwon, Soon Woo Nam, Dong Jin Yoon, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Seok Whan Moon, Hong Seok Jang, Jae-Sung Park, Sin-Soo Jeun, Yong-Kil Hong, Si Hyun Bae International Journal of Clinical Oncology.2019; 24(6): 666. CrossRef
Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park Cancers.2019; 11(4): 509. CrossRef
Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis David Sooik Kim, Tae Seop Lim, Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Oidov Baatarkhuu, Seung Up Kim Digestive Diseases and Sciences.2019; 64(12): 3660. CrossRef
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang Cancer Chemotherapy and Pharmacology.2019; 84(4): 809. CrossRef
Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization Jung Hee Kim, Dong Hyun Sinn, Jeong-Hoon Lee, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi Digestive Diseases and Sciences.2018; 63(4): 1062. CrossRef
RETRACTED: LncRNA NR2F1‐AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR‐363 Hai Huang, Jie Chen, Cheng‐Ming Ding, Xin Jin, Ze‐Ming Jia, Jian Peng Journal of Cellular and Molecular Medicine.2018; 22(6): 3238. CrossRef
Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications Pil Soo Sung, Jeong Won Jang International Journal of Molecular Sciences.2018; 19(11): 3648. CrossRef
First
Prev
